KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.

Patricia M Campbell, Marcelo Cantarovich, Azim Gangji, Isabelle Houde, Anthony M Jevnikar, Felix-Mauricio Monroy-Cuadros, Peter W Nickerson, Michel R Pâquet, G V Ramesh Prasad, Lynne Senécal, Jean-Luc Wolff, Jason J Schwartz, David N Rush

Clin Transplant 39(1) e70067

PMID39739990
PMCIDPMC11683858
DOI10.1111/ctr.70067
发表日期2024-12-31
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图。
摘要

摘要

INTRODUCTION: Novel approaches to improve long-term outcomes in kidney transplant recipients are required. Here, we present the 5-year data from a multicenter, prospective, Phase 3b trial evaluating treatment outcomes with standard (STD) or low (LOW) dose prolonged-release tacrolimus (TAC) combined with ACEi/ARB or other antihypertensive therapy (OAHT) in Canadian kidney transplant recipients. METHODS: Adult de novo kidney transplant recipients were randomized 2 × 2 to STD or LOW dose TAC and ACEi/ARB or OAHT. Patients had received a first or second transplant from a living or deceased donor and had ≥ 1 human leukocyte antigen mismatch with their donor. RESULTS: There were 281 patients from 13 sites across Canada. Overall patient survival was 95.7% and was comparable between groups. Graft survival at study end was 89.7% in the LOW+OAHT group and 94.4%-97.1% in the other groups and BPAR, and Class II de novo donor-specific antibodies (dnDSA) were higher in the LOW+OAHT group than in the other groups. However, these differences were not statistically significant. Graft function, blood pressure (BP), and proteinuria were similar between the groups; however, between 2 and 5 years there was a 2-fold or greater increase in the use of ACEi/ARB in patients randomized initially to OAHT, mostly because of hypertension and proteinuria. There were no unexpected safety findings. CONCLUSION: Patients randomized to LOW TAC with renin-angiotensin system (RAS) blockade had similar outcomes at 5 years as patients treated with STD TAC with or without RAS blockade, whereas those randomized to LOW TAC without RAS blockade showed a non-significant trend towards more rejections and dnDSA TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00933231.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1(A) Mean tacrolimus daily dose and (B) mean tacrolimus trough levels (full analysis set). Nominal study time periods were predefined. Total daily dose defined as the last observation within the time period. For each subject, tacrolimus trough level is the average of all assessments over that time period. Target tacrolimus trough concentrations are indicated by the corresponding shaded areas. LOW, low‐dose tacrolimus; STD, standard‐dose tacrolimus.
非 KM Figure
FIGURE 2Parameters of graft function over time by treatment group (full analysis set): (A) mean eGFR (calculated using the CKD‐EPI formula), (B) serum creatinine concentration, and (C) urine protein:creatinine ratio. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; LOW, low‐dose tacrolimus; OAHT, other antihypertensive therapy; STD, standard‐dose tacrolimus.
非 KM Figure